Clinical Trials Logo

Clinical Trial Summary

ABSTRACT Introduction Residual or absent oxidase function in peripheral neutrophils may point to an inborn defect of neutrophil function - chronic granulomatous disease (CGD) - whereas low to normal oxidative burst capacity has been linked to variants in various members of the NADPH-complex. Aims To assess the clinical value of routinely measuring oxidative burst activity of granulocytes in pediatric patients diagnosed with very early onset IBD (VEO-IBD) and late onset IBD. Objectives To investigate possible correlations between neutrophil function and IBD disease activity and to inquire the presence of genetic variants in those with low to absent oxidative burst. To identify the rate of monogenic VEO-IBD in our cohort. Materials and Methods The proposal constitutes a collaborative effort among Romanian pediatric tertiary care centers to examine the value of assessing neutrophil function in all pediatric IBD patients. Children aged <18 years diagnosed with Crohn's disease, ulcerative colitis or IBD-undetermined and age-matched healthy controls are recruited. A DHR flow cytometry assay is performed in included subjects and controls. Reduced or absent burst activity will lead to genetic testing in search of overt immunodeficiency or susceptibility variants. All VEO-IBD patients will have an immunological work-up in search of a primary immunodeficiency. Expected Results We anticipate to include a number of 150 pediatric patients with IBD over 12 months from the three pediatric gastroenterology units in Bucharest, Romania. We expect to identify an overall diminished neutrophil function in IBD patients versus controls and possible variants in the NADPH-complex genes.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06162936
Study type Observational
Source National Institute for Mother and Child Health Alessandrescu Rusescu
Contact Alexis Virgil Cochino, MD, PhD
Phone +40723193648
Email alexis_virgil@yahoo.com
Status Recruiting
Phase
Start date November 1, 2023
Completion date February 2025

See also
  Status Clinical Trial Phase
Withdrawn NCT03278912 - Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Completed NCT04136028 - IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease Early Phase 1
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Terminated NCT03080480 - Pioglitazone Therapy for Chronic Granulomatous Disease Phase 1/Phase 2
Terminated NCT00394316 - Gene Therapy for Chronic Granulomatous Disease Early Phase 1
Recruiting NCT03910452 - Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide Early Phase 1
Terminated NCT02282904 - Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide Phase 1/Phase 2
Terminated NCT02926963 - Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease. N/A
Completed NCT00006417 - Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease Phase 2
Completed NCT00368446 - Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Terminated NCT05915897 - Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)
Terminated NCT00325078 - Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease Phase 1/Phase 2
Completed NCT00001317 - A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood Phase 4
Completed NCT03548818 - Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00578643 - Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease Phase 2
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Enrolling by invitation NCT06253507 - pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) Phase 1/Phase 2